Anticancer agent 231 (compound P5) exhibits notable cytotoxic effects and impairs the viability of TNBC cells. It reduces the proliferation of Hs578T and MDA MB 231 cells at concentrations of 1, 2, and 4 μM over periods of 14 and 8 days. Furthermore, at doses of 1, 2, and 4 μM for 12 hours, this agent diminishes the migratory abilities of Hs578T cells. At concentrations of 1 and 2 μM, it inhibits tumor stemness and enhances the sensitivity of TNBC cells to paclitaxel. Lastly, Anticancer agent 231 targets the EGFR-ERK 1/2 axis to inhibit TNBC cells at two dosing ranges, 1, 2, 4 μM and 5, 10, 20 μM.

Anticancer agent 231 (化合物 P5) 显示出对TNBC细胞具有显著的抗生长效果，并可降低其存活率。在浓度为1, 2, 4 μM且处理时间为14天和8天的条件下，该化合物能有效抑制Hs578T细胞和MDA MB 231细胞的增殖。此外，治疗12小时后，1, 2, 4 μM的Anticancer agent 231 (化合物 P5) 显著抑制了Hs578T细胞的迁移能力。在1, 2 μM浓度下，该化合物不仅抑制肿瘤干性，还能增强TNBC细胞对紫杉醇的敏感性。Anticancer agent 231 (化合物 P5) 还通过影响EGFR-ERK 1/2 信号轴，以浓度1, 2, 4 μM; 5, 10, 20 μM 抑制TNBC细胞生长。